MFN drug pricing deals cover 89% of market as Moderna doubles

The White House's most-favored-nation drug pricing push now spans 26 manufacturers covering 89% of the branded U.S. market, yet the policy is reshaping investment flows more than patient bills, with Moderna's shares doubling on the arrangement.

"While the direct pricing impact of MFN may be limited, the policy is likely to further accelerate the shift of pharmaceutical manufacturing to the United States," said Diederik Stadig, economist at ING.

The latest round, announced Aug. 31, added nine mid-sized manufacturers — Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB — that agreed to give state Medicaid programs access to MFN pricing and committed at least $19.6 billion in U.S. manufacturing investment. Combined with earlier tariff and MFN rounds, total announced industry commitments approach $670 billion, according to ING estimates.

The direct hit to branded margins stays contained because the U.S. generates roughly half of global pharma revenue and often two-thirds of branded profits, giving companies room to absorb lower prices. The bigger consequence is geographic. Europe, whose national prices serve as the MFN benchmark, is losing appeal as a launch market: drug applications at the European Medicines Agency fell 25% in the first four months of 2026 from a year earlier, while the continent's share of global clinical trials dropped to about 20% in 2024 from roughly 35% in 2009, per ING.

Moderna's doubling and the sector read

Moderna's overnight doubling — the sharpest single-company reaction to the framework — reflects investors pricing out the uncertainty that had hung over drug-pricing policy rather than any change in the company's fundamentals. The move has fueled expectations that other healthcare names could follow as more manufacturers sign on, though the White House has not named further targets. The framework's expansion to mid-sized biopharma extends pricing discipline beyond the industry's largest players to companies that depend on future revenue expectations to fund research.

For the nine newest signatories, the deals pair price concessions with onshoring pledges. CSL, the King of Prussia, Pennsylvania-based maker of hemophilia and immune-deficiency therapies, entered separate Medicaid and Commerce agreements tied to a previously announced $1.5 billion expansion of its Kankakee, Illinois plant, which the company expects to create at least 300 manufacturing jobs. Several companies also donated strategic drug reserves, including UCB's 163 tons of levetiracetam and Teva's 45 metric tons of metronidazole.

Europe's response looms

The MFN push extends a drug-pricing crackdown that began with the Inflation Reduction Act's Medicare negotiation provisions, which set the first negotiated prices for a batch of top-selling drugs. MassBio, the Massachusetts biotechnology trade group, has argued that codifying MFN through Congress would lock in terms that risk undermining investment in new medicines, particularly for smaller and emerging companies that rely on future revenue expectations to attract capital.

What happens next hinges on whether the White House presses the remaining manufacturers outside the 89% coverage into similar deals, and whether European governments respond with coordinated price increases or broader market-access reforms. ING's Stadig said the U.S. price pressure "will not go away," leaving Europe to weigh higher prices against the risk of ceding more manufacturing and clinical development to the United States.

This article is for informational purposes only and does not constitute investment advice.